Search results for "harm"

showing 10 items of 13866 documents

S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.

2019

The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recomm…

medicine.medical_specialtyTuberculosisAdolescentMEDLINEDermatologyDiseaseDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritisBiological Factors0302 clinical medicinePharmacotherapyQuality of life (healthcare)PsoriasismedicineHumansPsoriasisChildBiosimilar PharmaceuticalsTonsillectomybusiness.industryVaccinationmedicine.diseaseSkin CareAnti-Bacterial AgentsFamily medicineUltraviolet TherapyDermatologic AgentsbusinessGuttate psoriasisImmunosuppressive AgentsJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDGReferences
researchProduct

Proliferative effect of acetylcholine on rat trachea epithelial cells is mediated by nicotinic receptors and muscarinic receptors of the M1-subtype.

2003

Acetylcholine (ACh), synthesized in mammalian non-neuronal cells such as epithelial cells of the airways, digestive tract and skin, is involved in the regulation of basic cell functions (so-called non-neuronal cholinergic system). In the present experiments rat trachea epithelial cells have been cultured to study the proliferative effect of applied ACh by [3H]thymidine incorporation. ACh (exposure time 24 h) caused a concentration-dependent increase in cell proliferation with a doubling of the [3H]thymidine incorporation at a concentration of 0.1 microM. This effect was partly reduced by 30 microM tubocurarine and completely abolished by the additional application of 1 microM atropine. The …

medicine.medical_specialtyTubocurarineMuscarinic AntagonistsNicotinic AntagonistsBiologyReceptors NicotinicGeneral Biochemistry Genetics and Molecular BiologyRats Sprague-DawleyInternal medicineMuscarinic acetylcholine receptormedicineMuscarinic acetylcholine receptor M4AnimalsGeneral Pharmacology Toxicology and PharmaceuticsNicotinic AntagonistReceptor Muscarinic M1Muscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2Epithelial CellsGeneral MedicineMolecular biologyPirenzepineReceptors MuscarinicAcetylcholineRatsTracheaAtropineEndocrinologyAcetylcholineCell Divisionmedicine.drugThymidineLife sciences
researchProduct

Platelet Function During Ticlopidine and Eicosapentaenoic Acid Administration in Patients with Coronary Heart Disease

2010

Antiplatelet drugs have been reported to be useful in unstable angina. This study was designed to investigate the effects of simultaneous administration of ticlopidine and eicosapentaenoic acid (EPA) on platelet function in coronary heart disease (CHD) patients. Ticlopidine significantly reduced platelet aggregation induced by ADP and collagen with no effect on arachidonate metabolism. The aggregation responses to collagen, ADP and arachidonate were not altered significantly by EPA (as fish oil) intake whereas thromboxane A(2) formation was reduced, but not completely inhibited. Combined therapy seems to achieve a more marked degree of inhibition of aggregation together with a fall in the u…

medicine.medical_specialtyUnstable anginabusiness.industryMetaboliteHematologyGeneral MedicinePharmacologyFish oilmedicine.diseaseEicosapentaenoic acidchemistry.chemical_compoundThromboxane A2chemistryInternal medicinemedicineCardiologyPlateletPlatelet activationTiclopidinebusinessmedicine.drugPlatelets
researchProduct

The pharmacological rationale for combining muscarinic receptor antagonists and beta-adrenoceptor agonists in the treatment of airway and bladder dis…

2014

Highlights • Muscarinic receptors increase smooth muscle tone in airways and urinary bladder. • β-Adrenoceptors relax smooth muscle tone and oppose muscarinic contraction. • Opposition involves transmitter release, signal transduction and receptor expression. • This supports the combined use of muscarinic antagonists and β-adrenoceptor agonists.

medicine.medical_specialtyUrologyDiseaseMuscarinic AntagonistsPharmacologyArticleβ adrenoceptorchemistry.chemical_compoundInternal medicineReceptors Adrenergic betaMuscarinic acetylcholine receptorDrug DiscoveryMuscarinic acetylcholine receptor M4RAT URINARY-BLADDERMedicineAnimalsHumansCyclic adenosine monophosphateADRENERGIC RELAXATIONLung Diseases ObstructivePROTEIN-KINASE-CReceptorTRACHEAL SMOOTH-MUSCLEPharmacologybusiness.industryUrinary Bladder DiseasesMuscarinic acetylcholine receptor M3Muscarinic acetylcholine receptor M2ACETYLCHOLINE-RELEASEAdrenergic beta-Agonistsmedicine.diseaseReceptors MuscarinicEndocrinologyNONNEURONAL CHOLINERGIC SYSTEMchemistryGUINEA-PIG TRACHEADrug Therapy CombinationCYCLIC ADENOSINE-MONOPHOSPHATECA2+-ACTIVATED K+ CHANNELAirwaybusinessUrinary bladder diseaseAUTORADIOGRAPHIC VISUALIZATIONAcetylcholinemedicine.drug
researchProduct

Dopaminergic modulation of evoked vasopressin release from the isolated neurohypophysis of the rat

1982

1. Neurointermediate lobes of rat pituitaries were incubated in Locke or Krebs solution, and the vasopressin released into the medium was assayed on the blood pressure of the pithed rat or by a radioimmunological procedure. Release of vasopressin over resting levels was evoked either by incubation with 60 mM KCl (high K) solution or by electrical stimulation of the pituitary stalk. Two different kinds of electrical stimulation were carried out. Procedure A (1 ms, 10 Hz, 5 times for 1 min within 10 min) induced a vasopressin overflow which was greatly calcium-dependent but only insignificantly sensitive to tetrodotoxin (TTX). Procedure B (0.2 ms, 15 Hz, 10 s trains with 10 s intervals for 10…

medicine.medical_specialtyVasopressinApomorphineVasopressinsDopamineStimulationTetrodotoxinIn Vitro TechniquesReceptors DopaminePituitary Gland PosteriorDopamineInternal medicinemedicineAnimalsBromocriptineEndogenous opioidPharmacologyNaloxoneChemistryDopaminergicRats Inbred StrainsGeneral MedicineElectric StimulationRatsFlupenthixolApomorphineEndocrinologyDopamine receptorFemaleEndorphinsSulpirideSulpiridemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

Differential effects of potassium channel blockers on neurohypophysial release of oxytocin and vasopressin. Evidence for frequency-dependent interact…

1988

Isolated rat neurohypophyses were fixed by their stalks to a platinum wire electrode and superfused with Krebs-HEPES solution. Vasopressin and oxytocin released into the medium were determined by specific radioimmunoassays. Hormone secretion was increased by electrical stimulation of the pituitary stalk at different frequencies. The effects of several potassium channel blockers, tetraethylammonium (TEA) ions, 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP) were tested. The release of vasopressin and oxytocin evoked by electrical stimulation with 900 pulses at 15 Hz (about 900 and 1,000 μU, respectively) was about 10 times higher than that evoked by 900 pulses at 3 Hz. Both 10 and 3…

medicine.medical_specialtyVasopressinCromakalimPotassium ChannelsVasopressinsRadioimmunoassayNeuropeptideAminopyridinesStimulation(+)-NaloxoneOxytocinPituitary Gland PosteriorInternal medicinemedicineAnimalsBenzopyransPyrroles4-AminopyridineEndogenous opioidPharmacologyChemistryNaloxoneTetraethylammoniumPotassium channel blockerRats Inbred StrainsGeneral MedicineTetraethylammonium CompoundsPotassium channelElectric StimulationRatsEndocrinologyOxytocinFemaleEndorphinsAmifampridinehormones hormone substitutes and hormone antagonistsmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

La auténtica dimensión del colesterol-no-HDL: colesterol aterogénico

2016

Lowe density lipoproteins (LDL) are the causal agent of cardiovascular diseases. In practice, we identify LDL with cholesterol transported in LDL (cLDL). So, cLDL has become the major target for cardiovascular prevention. Howewer, we have progressive evidences about the role of triglycerides rich lipoproteins, particularly those very low density lipoprotein (VLDL) in promotion and progression of atherosclerosis, that leads cholesterol in VLDL and its remanents as a potential therapeutic target. This feature is particularly important and of a great magnitude, in patients with hypertiglyceridemia. We can to considere, that the non-HDL cholesterol -cLDL+cVLDL+c-remmants+Lp(a)- is the real meas…

medicine.medical_specialtyVery low-density lipoproteinHigh risk patientsbusiness.industryCholesterolHypertriglyceridemia030204 cardiovascular system & hematologymedicine.disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePostprandialEndocrinologyCardiovascular preventionchemistryInternal medicineNon hdl cholesterolmedicinelipids (amino acids peptides and proteins)Pharmacology (medical)In patient030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis.

2020

Background: The comparative efficacy of pirfenidone, nintedanib, and pamrevlumab in slowing the rate of forced vital capacity (FVC) decline and mortality in patients with idiopathic pulmonary fibrosis (IPF) is unknown. Objective: To perform a systematic review and meta-analysis (MA) of these drugs for IPF. Methods: We searched CENTRAL, PubMed, EMBASE, ClincalTrials.gov, and the World Health Organization’s registry databases up to March 2020. Phase II/III randomized controlled trials in adults with IPF were eligible. The random-effect model was implemented calculating the effect size and respective 95% CI as Cohen’s d for change from baseline FVC (in percentage predicted and liters) and odds…

medicine.medical_specialtyVital capacityIndolesPyridones03 medical and health scienceschemistry.chemical_compoundFEV1/FVC ratioIdiopathic pulmonary fibrosis0302 clinical medicineInternal medicinemedicineHumansPharmacology (medical)In patient030212 general & internal medicinebusiness.industryPirfenidonemedicine.diseaseIdiopathic Pulmonary FibrosisTreatment Outcome030228 respiratory systemchemistryMeta-analysisNintedanibbusinessAll cause mortalitymedicine.drugThe Annals of pharmacotherapy
researchProduct

The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study.

2020

Abstract Aims Although depressive symptoms are highly prevalent in patients receiving oral anticoagulation (OAC), the relevance of depression for the outcome of anticoagulated individuals is unknown. Methods and results We analysed data from the multicentre cohort study thrombEVAL (NCT01809015) investigating the efficacy of OAC with vitamin K antagonists. There was an independent study monitoring, and an independent review panel assessed the endpoints. Out of n = 1558 participants, information about depressive symptoms, as measured by the two-item screener of the patient health questionnaire (PHQ-2), was available in n = 1405 individuals. The mean follow-up period was 28.04 months, with a s…

medicine.medical_specialtyVitamin KProportional hazards modelbusiness.industryDepressionHazard ratioAnticoagulantsVitamin kConfidence intervalPatient Health QuestionnaireCohort StudiesInternal medicineThromboembolismmedicineHumansPharmacology (medical)Cardiology and Cardiovascular MedicineAdverse effectbusinessDepression (differential diagnoses)Cohort studyEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

2016

ABSTRACTIntroduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists.…

medicine.medical_specialtyVitamin KPyridonesaspirinmedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyDabigatranAnticoagulation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanmedicineHumansatrial fibrillationPharmacology (medical)030212 general & internal medicineIntensive care medicineRivaroxabanAspirinbusiness.industryGeneral Neurosciencenon vitamin-K oral anticoagulantWarfarinAnticoagulantsreverse therapyAtrial fibrillationThrombolysismedicine.diseasemeasure of monitoringStrokewarfarinchemistryAnesthesiaPyrazolesApixabanstroke preventionNeurology (clinical)businessmedicine.drugExpert Review of Neurotherapeutics
researchProduct